Bayer, Onyx Start Phase III Nexavar Study On Thyroid Cancer
October 23 2009 - 3:14AM
Dow Jones News
German chemical and pharmaceutical company Bayer AG (BAYN.XE)
and Onyx Pharmaceuticals Inc. (ONXX) said Friday they are starting
a phase III trial of Nexavar (sorafenib) tablets in patients with
non-responsive thyroid cancer.
MAIN FACTS:
-Around 400 thyroid cancer patients with no prior systemic
therapy will enroll in a randomized, placebo-controlled study.
-The study's endpoint is progression-free survival, as well as
overall survival, time to progression and response rate.
-Nexavar is an oral anti-cancer therapy approved in more than 80
countries for liver cancer, and in more than 90 countries for
patients with advanced kidney cancer.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024